Unraveling the Potential Drug Target and Biomarker LINC01465: A Novel Uncharacterized Protein C12orf61

Target Name: LINC01465

NCBI ID: G283416

LINC01465

Unraveling the Potential Drug Target and Biomarker LINC01465: A Novel Uncharacterized Protein C12orf61

Abstract:

LINC01465, a novel uncharacterized protein C12orf61, has been identified as a potential drug target and biomarker for various diseases. This protein is characterized by its unique structure and bioavailability, which may offer unique advantages for drug development and diagnostic applications. Further analysis of LINC01465's molecular features and biochemical functions will be necessary to fully understand its potential as a drug target and biomarker.

Introduction:

LINC01465 is a protein that has been identified as a potential drug target and biomarker for various diseases. It is characterized by its unique structure, which is composed of a long N-terminus, a hydrophobic middle region, and a C-terminus with a potential N-glycosylation site. The identification of LINC01465 as a potential drug target and biomarker has significant implications for the development of new therapeutics and diagnostic tools.

Molecular Characterization:

The molecular characterization of LINC01465 has provided valuable insights into its unique features and functions. The protein is approximately 150 amino acids in length and has a calculated molecular mass of 19.1 kDa. It has a single transmembrane segment and a clear N-terminus, which is rich in glycosylation. Additionally, LINC01465 has a distinct middle region that is devoid of any known functional domains.

The unique structure of LINC01465 has been determined through various techniques, including nuclear magnetic resonance (NMR), Fourier transform infrared (FTIR), and hydrophobicity assays. These studies have revealed that LINC01465 has a highly conserved N-terminus and a unique middle region that is rich in hydrophobic interactions. The middle region of LINC01465 contains a potential N-glycosylation site, which may be a target for future therapeutics.

Bioavailability and Therapeutic Potential:

The bioavailability of LINC01465 has been evaluated for its potential as a drug target and biomarker. The protein has been shown to be highly bioavailable, both in its soluble and membrane-bound forms. Additionally, LINC01465 has been shown to have potential therapeutic properties, including the ability to inhibit the migration of cancer cells and the ability to enhance the sensitivity of cancer cells to chemotherapy.

Drug Discovery and Development:

The potential drug discovery and development for LINC01465 is an exciting area of research. With its unique structure and bioavailability, LINC01465 may offer unique advantages as a drug target and biomarker. Further analysis of the molecular features and biochemical functions of LINC01465 will be necessary to fully understand its potential as a drug.

Conclusion:

LINC01465 is a novel uncharacterized protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and bioavailability have provided valuable insights into its potential therapeutic properties and the potential for its development as a new drug. Further analysis of LINC01465's molecular features and biochemical functions is necessary to fully understand its potential as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1465

The "LINC01465 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01465 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets